Slide 1: Sharewise Webinar
NASDAQ: IMRN IMMUFeNn ASX: IMC Sharewise Webinar Steven Lydeamore Chief Executive Officer g JULY 2024
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressio
Slide 3: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview Two commercially available oral immunotherapeutic products — Travel
Slide 4: Technology platform
Technology platform Immuron’s proprietary technology platform combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and can be used to target virus
Slide 5: Travelan mechanism: with and without Travelan
thout Travelan® Bacteria attach to gut wall and infect Bacteria neutralized by Travelan” antibodies 2003700 SsPECcsee
Slide 6: Status of product portfolio and key milestones
Status of product portfolio and key milestones Travelan® MTEC 21-10-013 grant Phase 2 randomized clinical challenge study to examine a dosing regimen for Travelan® more suited to the military IMM-124E (Travelan®) IND 29087 FDA approval Dec 22 Top-line data 7 March 2024 Additional topline data - end
Slide 7: Clinically proven: Travelan USA market
snIcALty PROVEN: SubiSoncpmorecron travelan’- USA Market FY2g: launch on amazon.com and Walmart.com Planning for increased market penetration in FY25 Chief Commercial Officer has 20+ year’s experience with local and global (Asia, UK) commercial leadership roles with GSK and P&G 's diarrho Evaluating
Slide 8: Net Sales A#039;000
FY20 Net Sales AS'000 YTDMarFY24
Slide 9: Travelan Phase 2 CHIM study design
+ Healthy volunteers were recruited and randomized to receive a single daily oral dose of 1200 mg of Travelan® or placebo. Dosing commenced 2 days prior to challenge with ETEC strain H10407 and continued for 7 days. 60 subjects completed the inpatient challenge component of this current clinical stu
Slide 10: World first triple mechanism of action for CDI
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI Indication / Target Population Product Description / Mechanism of Action Dosage and ROA Efficacy Safety / Tolerability ImmMUren IMM-529 will be indicated for the treatment of recurrent C. difficile infection * Novel antibody-containing therapeutic which
Slide 11: Scientific references
Scientific references Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC- induced diarrhea in up to 90% of volunteers indinavian J 46:7-8, 862-868, DOI: 10. 011.574726 Clinical Evaluation of Travelan® an Oral Prophylactic for Prevention of Travelers’ . -
Slide 12: Contact information
ImMMUren STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: [XQ] EMAIL: STEVE@IMMURON.COM hk PHONE: AUSTRALIA: +61 438 027 172